Abstract
Immune-mediated diseases (IMD) encompass a wide range of autoimmune and inflammatory disorders with aetiology related to immune system dysfunction, signifying a disease area with great potential for drug repurposing. In this study, we employed the genetically informed Mendelian Randomization (MR) method with two distinct exposure types: immune blood cell abundance and protein quantitative trait loci (pQTL) to validate and repurpose 834 drug targets which have been investigated for IMD treatment. Utilizing two-sample MR, we first established causal relationships between major peripheral immune cell types and 14 IMD. Robust associations, particularly with eosinophils, were confirmed across diseases such as asthma, eczema, sinusitis, and rheumatoid arthritis, revealing 59 high-confidence relationships. Intragenic variants associated with causal immune cell types were then extracted to create instruments for 371 existing IMD drug targets (“intermediate trait” MR). In parallel, we leveraged four large blood plasma protein QTL datasets to obtain complementary instruments for 361 targets (“pQTL” MR). In the intermediate trait MR analysis, we identified 811 gene-IMD associations (p-value < 0.05; 137 pairs below Bonferroni-adjusted p-value threshold), 169 of which were supported by strong colocalisation evidence (PPH4 ≥ 0.8). In the pQTL MR analysis, we similarly found 841 protein-IMD associations (p-value < 0.05; 90 pairs below Bonferroni-adjusted p-value threshold), 83 of which were confirmed with colocalization. Comparison with a list of approved drugs indicated low sensitivities across disease outcomes for both exposure types (intermediate trait MR: 0.49 ± 0.23 SD, pQTL MR: 0.28 ± 0.12 SD). Drug targets identified in the pQTL and intermediate trait MR analyses show limited overlap (13% at nominal p-value and 36% at Bonferroni-adjusted p-value threshold), presenting a comprehensive source of drug repurposing opportunities when the two approaches are combined.
Data availability
We accessed the following immune cell GWAS summary statistics via OpenGWAS (https://gwas.mrcieu.ac.uk/)111: ebi-a-GCST90002292, ebi-a-GCST004634, ebi-a-GCST90002380, ebi-a-GCST90002298, ebi-a-GCST004617, ebi-a-GCST90002382, ebi-a-GCST004614, ebi-a-GCST004608, ebi-a-GCST90002316, ebi-a-GCST90002389, ebi-a-GCST90002340, ebi-a-GCST90002394, ebi-a-GCST004626, ebi-a-GCST90002351, ebi-a-GCST004623, ebi-a-GCST90002399, ebi-a-GCST004620, ebi-a-GCST004624, ebi-a-GCST004613, ebi-a-GCST90002374. We accessed the following immune-mediated disease GWAS summary statistics via OpenGWAS (https://gwas.mrcieu.ac.uk/)111: ebi-a-GCST90014325, ebi-a-GCST006862, ebi-a-GCST004132, ebi-a-GCST004131, ieu-b-18, ebi-a-GCST90019016, ebi-a-GCST002318, ebi-a-GCST003156, ebi-a-GCST010681, ebi-a-GCST004133. We obtained the following immune-mediated disease GWAS summary statistics from FinnGen ver. 9 (https://www.finngen.fi/en/access_results)42: M13_ANKYLOSPON, J10_CHRONSINUSITIS, L12_ATOPIC and NHGRI-EBI GWAS Catalog (http://www.ebi.ac.uk/gwas)112: GCST90244787, GCST90027899, GCST90010715. UKBB pQTL dataset58 was accessed via [https://metabolomips.org/ukbbpgwas/](https:/metabolomips.org/ukbbpgwas), deCODE pQTL dataset56 was accessed via [https://www.decode.com/summarydata/](https:/www.decode.com/summarydata) , ARIC pQTL dataset55 was accessed via [http://nilanjanchatterjeelab.org/pwas/](http:/nilanjanchatterjeelab.org/pwas).
References
He, M. et al. Immune-Mediated Diseases Associated With Cancer Risks. JAMA Oncol. 8, 209–219 (2022).
El-Gabalawy, H., Guenther, L. C. & Bernstein, C. N. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J. Rheumatol. Suppl. 85, 2–10 (2010).
Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375–388 (2020).
McInnes, I. B. & Gravallese, E. M. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat. Rev. Immunol. 21, 680–686 (2021).
Pisetsky, D. S. Pathogenesis of autoimmune disease. Nat. Rev. Nephrol. 19, 509–524 (2023).
Begley, C. G. et al. Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. Sci. Transl Med. 13, eabd5524 (2021).
Petitdemange, A., Blaess, J., Sibilia, J., Felten, R. & Arnaud, L. Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis. Ther. Adv. Musculoskelet. Dis. 12, 1759720X20969261 (2020).
David, T., Ling, S. F. & Barton, A. Genetics of immune-mediated inflammatory diseases. Clin. Exp. Immunol. 193, 3–12 (2018).
Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).
Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic evidence on clinical success. medRxiv https://doi.org/10.1101/2023.06.23.23291765 (2023).
King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLOS Genet. 15, 1–20 (2019).
Gill, D. et al. Mendelian randomization for studying the effects of perturbing drug targets. Wellcome open. Res. 6, 16 (2021).
Davies, N. M. & Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. BMJ 362, (2018).
Daghlas, I. & Gill, D. Mendelian randomization as a tool to inform drug development using human genetics. Camb. Prism Precis Med. 1, e16 (2023).
Schmidt, A. F. et al. Genetic drug target validation using Mendelian randomisation. Nat. Commun. 11, 3255 (2020).
Zhao, H. et al. Proteome-wide Mendelian randomization in global biobank meta-analysis reveals multi-ancestry drug targets for common diseases. Cell Genomics 2, e100195 (2022).
Rasooly, D. et al. Genome-wide association analysis and Mendelian randomization proteomics identify drug targets for heart failure. Nat. Commun. 14, 3826 (2023).
Yao, M. et al. Deciphering proteins in Alzheimer’s disease: A new Mendelian randomization method integrated with AlphaFold3 for 3D structure prediction. Cell Genomics 4, (2024).
Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives for large population-based studies. Nat. Rev. Genet. 22, 19–37 (2021).
Zheng, J. et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat. Genet. 52, 1122–1131 (2020).
Daghlas, I. et al. Genetic Evidence for Repurposing of GLP1R (Glucagon-Like Peptide‐1 Receptor) Agonists to Prevent Heart Failure. J. Am. Heart Assoc. 10, e020331 (2021).
Georgakis, M. K. et al. Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes. Circ. Genomic Precis Med. 13, e002872 (2020).
Cronjé, H. T. et al. Genetic evidence implicating natriuretic peptide receptor-3 in cardiovascular disease risk: a Mendelian randomization study. BMC Med. 21, 158 (2023).
Zhou, G. et al. Exploring the association and causal effect between white blood cells and psoriasis using large-scale population data. Front. Immunol. 14, 1043380 (2023).
Pongdee, T., Bielinski, S. J., Decker, P. A., Kita, H. & Larson, N. B. White blood cells and chronic rhinosinusitis: a Mendelian randomization study. Allergy Asthma Clin. Immunol. 18, 98 (2022).
Schuster, C. et al. The Autoimmunity-Associated Gene CLEC16A Modulates Thymic Epithelial Cell Autophagy and Alters T Cell Selection. Immunity 42, 942–952 (2015).
He, D., Liu, L., Shen, D., Zou, P. & Cui, L. The Effect of Peripheral Immune Cell Counts on the Risk of Multiple Sclerosis: A Mendelian Randomization Study. Front. Immunol. 13, 867693 (2022).
Zeng-Yun-Ou, Z., Zhong-Yu, J. & Wei, L. Bidirectional associations between eosinophils, basophils, and lymphocytes with atopic dermatitis: A multivariable Mendelian randomization study. Front. Immunol. 13, e1001911 (2022).
Guyatt, A. et al. Mendelian randomisation of eosinophils and other cell types in relation to lung function and disease. Thorax 78, 496–503 (2023).
Kim, H. Y., DeKruyff, R. H. & Umetsu, D. T. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat. Immunol. 11, 577–584 (2010).
Hammad, H. & Lambrecht, B. N. The basic immunology of asthma. Cell 184, 1469–1485 (2021).
Facheris, P., Jeffery, J., Del Duca, E. & Guttman-Yassky, E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell. Mol. Immunol. 20, 448–474 (2023).
Walsh, C. M. et al. Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis. Elife 8, e48448 (2019).
Crow, M. K. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann. Rheum. Dis. 82, 999–1014 (2023).
Baecher-Allan, C., Kaskow, B. J. & Weiner, H. L. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron 97, 742–768 (2018).
Williams, D. M. Clinical Pharmacology of Corticosteroids. Respir Care. 63, 655–670 (2018).
Cronstein, B. N. & Aune, T. M. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat. Rev. Rheumatol. 16, 145–154 (2020).
Allison, A. C. & Eugui, E. M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47, 85–118 (2000).
Astle, W. J. et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell 167, 1415–1429 (2016).
Chen, M. H. et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. Cell 182, 1198–1213e14 (2020).
Vuckovic, D. et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. Cell 182, 1214–1231e11 (2020).
Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613, 508–518 (2023).
Demenais, F. et al. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nat. Genet. 50, 42–53 (2018).
Valette, K. et al. Prioritization of candidate causal genes for asthma in susceptibility loci derived from UK Biobank. Commun. Biol. 4, 700 (2021).
Budu-Aggrey, A. et al. European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation. Nat. Commun. 14, 6172 (2023).
Chang, X. et al. A genome-wide association meta-analysis identifies new eosinophilic esophagitis loci. J. Allergy Clin. Immunol. 149, 988–998 (2022).
Stuart, P. E. et al. Transethnic analysis of psoriasis susceptibility in South Asians and Europeans enhances fine mapping in the MHC and genome wide. Hum. Genet. Genomics Adv. 3, 100069 (2022).
López-Isac, E. et al. Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms. Ann. Rheum. Dis. 80, 321–328 (2021).
Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376–381 (2014).
de Lange, K. M. et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256–261 (2017).
Patsopoulos, N. A. et al. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365, eaav7188 (2019).
Bentham, J. et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 47, 1457–1464 (2015).
Forgetta, V. et al. Rare Genetic Variants of Large Effect Influence Risk of Type 1 Diabetes. Diabetes 69, 784–795 (2020).
Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-sample Mendelian randomization. Genet. Epidemiol. 40, 597–608 (2016).
Zhang, J. et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat. Genet. https://doi.org/10.1038/s41588-022-01051-w (2022).
Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and disease. Nat. Genet. 53, 1712–1721 (2021).
Pietzner, M. et al. Mapping the proteo-genomic convergence of human diseases. Sci. (80-). 374, eabj1541 (2021).
Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature https://doi.org/10.1038/s41586-023-06592-6 (2023).
Delaneau, O. et al. Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel. Nat. Commun. 5, 3934 (2014).
Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, s13742-015-0047-8 (2015).
Thormann, A. et al. Flexible and scalable diagnostic fi ltering of genomic variants using G2P with Ensembl VEP. Nat. Commun. 1–10. https://doi.org/10.1038/s41467-019-10016-3 (2019).
Yuan, Z. et al. Testing and controlling for horizontal pleiotropy with probabilistic Mendelian randomization in transcriptome-wide association studies. Nat. Commun. 11, 3861 (2020).
Holmes, M. V., Richardson, T. G., Ference, B. A. & Davies, N. M. Davey Smith, G. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nat. Rev. Cardiol. 18, 435–453 (2021).
Eldjarn, G. H. et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature https://doi.org/10.1038/s41586-023-06563-x (2023).
Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, e34408 (2018).
Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 50, 693–698 (2018).
Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet. Epidemiol. 40, 304–314 (2016).
Bowden, J. et al. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int. J. Epidemiol. 45, 1961–1974 (2016).
Wallace, C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLOS Genet. 16, e1008720 (2020).
Zuber, V. et al. Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. Am. J. Hum. Genet. https://doi.org/10.1016/j.ajhg.2022.04.001 (2022).
Wallace, C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet. 16, 1–20 (2020).
Mullen, A., Blunck, M., Kalbfleisch, E., Möller, E. & Rohbeck, H. G. Assessment, from an industrial user perspective, of some major competitor information files on pharmaceutical development products. J. Inf. Sci. 23, 9–23 (1997).
Bhattacharya, S. et al. ImmPort: disseminating data to the public for the future of immunology. Immunol. Res. 58, 234–239 (2014).
Breuer, K. et al. InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation. Nucleic Acids Res. 41, D1228–D1233 (2013).
Chepelev, I., Harley, I. T. W. & Harley, J. B. Modeling of horizontal pleiotropy identifies possible causal gene expression in systemic lupus erythematosus. Front Lupus 1, e1234578 (2023).
Sobczyk, M. K., Richardson, T. G., Leyden, G. M. & Gaunt, T. R. Distinct pathway-based effects of blood pressure and body mass index on cardiovascular traits: comparison of novel Mendelian Randomization approaches. medRxiv (2023). https://doi.org/10.1101/2023.10.31.23297593
Kennedy, W. P. et al. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis Res. Ther. 16, 467 (2014).
Folci, M., Ramponi, G., Arcari, I., Zumbo, A. & Brunetta, E. Eosinophils as Major Player in Type 2 Inflammation: Autoimmunity and Beyond BT - Cell Biology and Translational Medicine, Volume 14: Stem Cells in Lineage Specific Differentiation and Disease. in (ed Turksen, K.) 197–219 (Springer International Publishing, doi:https://doi.org/10.1007/5584_2021_640. (2021).
Caldwell, J. M., Paul, M. & Rothenberg, M. E. Novel immunologic mechanisms in eosinophilic esophagitis. Curr. Opin. Immunol. 48, 114–121 (2017).
Elias, P. M. & Steinhoff, M. “Outside-to-Inside” (and Now Back to“Outside”) Pathogenic Mechanisms in Atopic Dermatitis. J. Invest. Dermatol. 128, 1067–1070 (2008).
Egawa, G. & Kabashima, K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J. Allergy Clin. Immunol. 138, 350–358e1 (2016).
Chen, H., Wu, X., Xu, C., Lin, J. & Liu, Z. Dichotomous roles of neutrophils in modulating pathogenic and repair processes of inflammatory bowel diseases. Precis Clin. Med. 4, 246–257 (2021).
Hirahara, K., Aoki, A. & Nakayama, T. Pathogenic helper T cells. Allergol. Int. 70, 169–173 (2021).
Sakaguchi, S. et al. Regulatory T Cells and Human Disease. Annu. Rev. Immunol. 38, 541–566 (2020).
Park, C. O. & Kupper, T. S. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat. Med. 21, 688–697 (2015).
Lee, D. S. W., Rojas, O. L. & Gommerman, J. L. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat. Rev. Drug Discov. 20, 179–199 (2021).
Gu, J. et al. Assessing the causal relationship between immune traits and systemic lupus erythematosus by bi-directional Mendelian randomization analysis. Mol. Genet. Genomics. 298, 1493–1503 (2023).
Swart, J. F., de Roock, S. & Prakken, B. J. Understanding inflammation in juvenile idiopathic arthritis: How immune biomarkers guide clinical strategies in the systemic onset subtype. Eur. J. Immunol. 46, 2068–2077 (2016).
Chen, M. et al. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin. Exp. allergy J. Br. Soc. Allergy Clin. Immunol. 51, 546–555 (2021).
Lawlor, D. A. & Tilling, K. Davey Smith, G. Triangulation in aetiological epidemiology. Int. J. Epidemiol. 45, 1866–1886 (2016).
Giambartolomei, C. et al. A Bayesian framework for multiple trait colocalization from summary association statistics. Bioinformatics 34, 2538–2545 (2018).
Wallace, C. A more accurate method for colocalisation analysis allowing for multiple causal variants. PLoS Genet 17, e1009440 (2021).
Schoeler, T. et al. Participation bias in the UK Biobank distorts genetic associations and downstream analyses. Nat. Hum. Behav. 7, 1216–1227 (2023).
Yarmolinsky, J., Bull, C. J., Walker, V. M., Nounu, A. & Smith, G. D. Mendelian randomization applied to pharmaceutical use: the case of metformin and lung cancer. Int. J. Epidemiol. 49, 1410–1411 (2020).
Zheng, J. et al. Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study. Diabetologia 65, 1664–1675 (2022).
Paternoster, L., Tilling, K. & Davey Smith, G. Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges. PLOS Genet. 13, e1006944 (2017).
Vignesh, P., Rawat, A., Sharma, M. & Singh, S. Complement in autoimmune diseases. Clin. Chim. Acta. 465, 123–130 (2017).
Zhao, J. H. et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat. Immunol. 24, 1540–1551 (2023).
Yazar, S. et al. Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. Science 376, eabf3041 (2022).
Kang, J. B. et al. Mapping the dynamic genetic regulatory architecture of HLA genes at single-cell resolution. Nat. Genet. 55, 2255–2268 (2023).
Harb, H. & Chatila, T. A. Mechanisms of Dupilumab. Clin. Exp. allergy J. Br. Soc. Allergy Clin. Immunol. 50, 5–14 (2020).
Langowski, J. et al. NKTR-358: a selective, first-in-class IL-2 pathway agonist which increases number and suppressive function of regulatory T cells for the treatment of immune inflammatory disorders. Arthritis Rheumatol. 69, suppl 10 (2017).
Silverberg, J. et al. A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis. Br. J. Dermatol. 191, ljae266.097 (2024).
Ferreira, R. C. et al. Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases. PLOS Genet. 9, 1–12 (2013).
Rosa, M. et al. A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. npj Genomic Med. 4, 1–10 (2019).
Taylor, P. C. et al. What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes? Ther. Adv. Musculoskelet. Dis. 16, 1759720X241283340 (2024).
Bachus, H. et al. IL-6 prevents Th2 cell polarization by promoting SOCS3-dependent suppression of IL-2 signaling. Cell. Mol. Immunol. 20, 651–665 (2023).
Group, T. L. M. S. S. & of British Columbia MS/MRI Analysis Group, T. U. TNF neutralization in MS. Neurology 53, 457 (1999).
Atassi, K. T. G., Lio, P. A. & J. Z. N. J. M. & Off-Label studies on anakinra in dermatology: a review. J. Dermatolog Treat. 33, 73–86 (2022).
Hwang, T. J. et al. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Intern. Med. 176, 1826–1833 (2016).
Elsworth, B. et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv https://doi.org/10.1101/2020.08.10.244293 (2020).
Sollis, E. et al. The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. Nucleic Acids Res. 51, D977–D985 (2023).
Funding
This work was funded by the UK Medical Research Council (MRC) as part of the MRC Integrative Epidemiology Unit (MC_UU_00032/03). This study was also supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
Author information
Authors and Affiliations
Contributions
MKS: Conceptualization, Formal analysis, Visualization, Writing – original draft, Writing – review and editingTG: Supervision, Writing – review and editing, Funding acquisition, Resources.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
The article uses previously published GWAS summary statistics. No separate ethical approval is required for this study. All subjects provided informed consent in the original studies. No human subjects were directly involved in this study.
Competing interests
TRG receives funding from Biogen and GlaxoSmithKline for unrelated research. M.K.S. declares no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sobczyk, M.K., Gaunt, T.R. Integrative mendelian randomization approaches for therapeutic target prioritisation in immune-mediated diseases. Sci Rep (2026). https://doi.org/10.1038/s41598-026-41818-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-41818-3
